Sempre Health offers a behavior-based pricing solution that aligns health plans and life sciences companies to dynamically adjust patients' out-of-pocket medication costs based on individual adherence and benefit design. The company operates a two-sided network connecting pharma manufacturers and health plans to implement its point-of-dispense pricing. Led by CEO Anurati Mathur, Sempre differentiates from traditional coupon and cash card programs by coordinating multiple stakeholders rather than delivering standalone discounts. The company plans to use new funding to accelerate growth of its network and to launch products for new patient populations. Sempre also intends to significantly increase the number of patients helped by its solution. The article does not disclose specific operating metrics or financials beyond the recent financing. Sempre Health builds a behavior-driven pricing platform that works with health plans and pharmaceutical companies to reduce patient costs for on-time prescription refills. The company combines technology, behavioral science and dynamic pricing to raise medication adherence and health outcomes. Led by CEO Anurati Mathur, Sempre operates a two-sided network of payors and pharma manufacturers. It aims to grow nationwide and increase the number of chronic disease patients who can access their medications. Sempre targets boosting members’ adherence to exceed 80% of days covered and to help save hundreds of billions of dollars in avoidable medical costs. The company is based in San Francisco, CA. Led by CEO Anurati Mathur, Sempre Health operates a two-sided network of payers and pharma manufacturers that dynamically adjusts patient copayments at the point of fill based on individual adherence and behavior. Its core product enables health plans to align member financial incentives with clinical priorities by letting members lower their costs through responsible actions such as filling prescriptions on time. Programs are designed to be consistent with formulary design and tied to reductions in overall cost of care. The company partners with multiple healthcare stakeholders rather than relying on traditional coupons and vouchers. Earlier in the year Sempre announced a partnership with Novo Nordisk to deliver dynamic discounts and engagement to diabetes patients, and it expected to have more than 15 pharma manufacturer and payer partners by Q4 2018. Sempre said it will use new funding to accelerate growth of its two-sided affordability marketplace. Sempre Health offers a behavior-based healthcare pricing platform that dynamically adjusts individual patients' co-payments based on adherence and behavior, applied seamlessly at the point of fill. The company works with health plans and pharmaceutical manufacturers and parses millions of prescription records to predict the right price for the right patient at the right time. Sempre's data integrations deliver those prices at any U.S. pharmacy and provide patients 24/7 SMS access to current discounts, explanations, and guidance to improve adherence. After graduating the Alchemist Accelerator and completing a favorable randomized controlled trial in 2016, Sempre is partnering with a large regional health plan to enroll heart patients and apply behavioral-economics–driven incentives via SMS. Founded in 2015 and based in San Francisco, the company aims to help patients lower costs over time while improving outcomes and reducing system-level spending. Financially, Sempre raised a $2.5M seed round last year from Social Capital.

Total raised

$46M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2023